Should I Buy NVNO? NVNO 2026 Analysis

Should You Buy enVVeno Medical Corp (NVNO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

10.420

1 Day change

11.44%

52 Week Range

196.700

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: price action is in a clear downtrend and has slipped below the nearby support zone.
There are no proprietary buy signals today (AI Stock Picker / SwingMax), so there’s no high-conviction timing edge to override the weak chart.
Options positioning is extremely call-heavy, but with zero volume today it does not confirm active bullish demand.
With no recent news catalysts and worsening losses in the latest reported quarter, the risk/reward does not favor an immediate entry.

Technical Analysis

Trend: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum.
Momentum: MACD histogram is negative (-0.0867) and expanding lower, confirming bearish momentum is strengthening.
RSI: RSI_6 at ~31.4 is near oversold territory (not a confirmed reversal signal by itself), implying the stock can still drift lower even if a bounce is possible.
Levels: Current price 9.13 is below S1 (9.417), which signals a breakdown of near-term support; next key support is S2 at 8.643. Upside recovery would first need to reclaim S1 (9.417) and then the pivot near 10.67.
Pattern-based forward view (provided): ~70% probability of -0.46% next day and -0.83% next week, but +7.77% next month—suggesting any upside is more “later” than “now,” which doesn’t match an impatient entry.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment (Open Interest): Put/Call OI ratio = 0.01 (overwhelmingly call-heavy OI: 12,719 calls vs 125 puts), which can be interpreted as bullish positioning, but can also reflect legacy positioning and not necessarily fresh demand.
Activity (Volume): Call volume = 0 and Put volume = 0 today → there is no real-time confirmation from options traders.
Volatility: 30D IV ~~44.66 with **very low IV percentile (~~5.18)** and IV rank (~1.8) → options are priced for relatively low volatility versus recent history (not a bullish signal by itself; often consistent with a quiet/illiquid name).

Technical Summary

Sell

Buy

Positive Catalysts

- Potential technical snapback: RSI near oversold raises the odds of a short-term bounce if buyers defend the 8.64–9.00 area.
- Options open interest is heavily call-skewed (OI PCR 0.01), which may indicate some market participants are positioned for upside.
- Pre-market was up (+1.92%), which can sometimes hint at dip-buying interest (not confirmed in regular-session trend yet).

Neutral/Negative Catalysts

- Strong bearish trend structure: bearish MA stack plus MACD histogram expanding negatively.
- Price is below the near-term support (S1 9.417), increasing risk of a move toward S2 (8.643).
- No news in the past week → no obvious event-driven catalyst to reverse the downtrend.
- Weak fundamental profile (pre-revenue, losses widening YoY) reduces confidence in sustained rallies.
- Hedge fund and insider trading trends are neutral—no supportive “smart money” accumulation signal in the provided data.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 0 (no YoY growth; still pre/near-revenue).
Profitability: Net income -4.539M, worse by -19.55% YoY (losses widening).
EPS: -7.88, down -35.88% YoY (deteriorating per-share results).
Gross margin: 0 (consistent with no revenue/limited commercial scale in the reported period).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there’s no visible Wall Street consensus trend to support an immediate buy.
Wall Street pros/cons view (based on provided dataset):
- Pros: none explicitly indicated (no upgrades/raised targets shown).
- Cons: absence of supportive analyst actions plus weak reported financial trajectory (worsening losses, no revenue).
Politicians/congress: No recent congress trading data available in the last 90 days (no signal from political/influential buying or selling in the provided data).

Analyst Rating

Wall Street analysts forecast NVNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVNO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 9.350

Low

Averages

High

Current: 9.350

Low

Averages

High

NVNO Should I Buy

NVNO Should I Buy

Should You Buy enVVeno Medical Corp (NVNO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data

People Also Watch